Ann: AusCann Investor Webinar Recording, page-6

The 10-15 year figure was for a traditional 'non-cannabinoid' drug pathway - basically a new chemical/ingredient. Cannabinoids aren't new, there is a lot known about them so that figure isn't relevant to Auscann.

The hard shell is definitely their first product and is therefore enormously important, so the focus is rightly there.
But I'm sure over the next few years they'll be looking at other innovations - that's the whole reason for the new labs.

I thought he was pretty clear on where they saw the value in the hard shell. IMO they are unquestionably valuable and will be more so after a (hopefully) successful phase 1 trial.